18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials
Authors
Keywords
<sup>18</sup>F-FDG PET/CT, Triple-negative breast cancer, HER2-positive breast cancer, Neoadjuvant treatment, Treatment response assessment, Pathological complete response, Prognosis
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 43, Issue 5, Pages 983-993
Publisher
Springer Nature
Online
2016-01-14
DOI
10.1007/s00259-015-3295-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
- (2015) O. Humbert et al. CLINICAL CANCER RESEARCH
- Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
- (2015) David Groheux et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer
- (2015) D. Groheux et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen
- (2015) D. Groheux et al. JOURNAL OF NUCLEAR MEDICINE
- Pathological complete response in breast cancer
- (2015) Elif Hindié et al. LANCET
- Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype
- (2015) David Groheux et al. RADIOLOGY
- Oncogene Pathway Activation in Mammary Tumors Dictates FDG-PET Uptake
- (2014) J. V. Alvarez et al. CANCER RESEARCH
- Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer
- (2014) David Groheux et al. EUROPEAN JOURNAL OF CANCER
- Early and delayed prediction of axillary lymph node neoadjuvant response by 18F-FDG PET/CT in patients with locally advanced breast cancer
- (2014) Ana María García Vicente et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy
- (2014) Olivier Humbert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- (2014) Sally F. Barrington et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- (2014) R. M. Connolly et al. JOURNAL OF NUCLEAR MEDICINE
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
- (2014) Bruno Coudert et al. LANCET ONCOLOGY
- Predicting pathological complete response in breast cancer early
- (2014) David Groheux LANCET ONCOLOGY
- FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
- (2013) Bas B. Koolen et al. BREAST
- HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
- (2013) D Groheux et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
- (2013) L S Rigter et al. BRITISH JOURNAL OF CANCER
- Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors
- (2013) David Groheux et al. CANCER
- Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer
- (2013) A. Bardia et al. CLINICAL CANCER RESEARCH
- Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy
- (2013) G. Zucchini et al. EUROPEAN JOURNAL OF CANCER
- Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy
- (2013) Bas B. Koolen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer
- (2013) Olivier Humbert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Comparison Between 18F-FDG PET Image-Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2013) M. Hatt et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
- (2013) G. Gebhart et al. JOURNAL OF NUCLEAR MEDICINE
- Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes
- (2012) O. Humbert et al. ANNALS OF ONCOLOGY
- Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse
- (2012) D. Groheux et al. JOURNAL OF NUCLEAR MEDICINE
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging—Prospective Assessment
- (2012) Ukihide Tateishi et al. RADIOLOGY
- Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis
- (2011) Yuting Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer
- (2010) J. M. Specht et al. CLINICAL CANCER RESEARCH
- Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim
- (2010) David Groheux et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
- (2010) David Groheux et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer
- (2009) A. Gil-Rendo et al. BRITISH JOURNAL OF SURGERY
- 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
- (2009) Joan Duch et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
- (2009) Amandeep Kumar et al. EUROPEAN RADIOLOGY
- Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
- (2008) Lisa K. Dunnwald et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease
- (2008) Julie R. Gralow et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
- (2008) Jörg Schwarz-Dose et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started